GVHD Symptoms

This article looks at GVHD symptoms. GVHD, Graft-versus-host-disease, is the most serious potential complication of an allogeneic stem cell transplantation. In GVHD, the transplanted bone marrow begins to attack a patient's organs. It occurs in as many as one half of all allogeneic stem cell transplant patients, and it can either be of the acute kind (occurring within about 100 days of the transplant) or of the chronic kind (occurring after those 100 days). The most common GVHD symptoms are as follows:

Acute GVHD symptoms:
Acute GVHD affects the skin, the liver, and the gastrointestinal tract. Thus GVHD symptoms include:

-- Diarrhea
-- Fever
-- Skin rashes
-- Jaundice
-- Abdominal cramps
-- Abdominal pain
-- Vomiting
-- Weight loss

Chronic GVHD symptoms
Chronic GVHD affects the skin, mouth, liver, eyes, GI tract, lungs, and joints. Thus GVHD symptoms include:

-- Dry eyes
-- Dry mouth
-- Hair loss
-- Pulmonary (lung) disorders
-- Digestive tract disorders
-- Hepatitis
-- Skin rash
-- Skin thickening

Because GVHD is a potentially life-threatening complication, doctors do what they can to try and prevent it from developing. They are not, however, always successful

Sources

MedlinePlus, Graft-Versus-Host-Disease

Medscape Reference, Graft-Versus-Host-Disease

Boyiadzis, Michael M. et al. Hematology-Oncology Therapy. 2007. New York: McGraw Hill, Medical Publishing Division, Ch. 50, "Complications and Follow-Up after Hematopoietic Stem Cell Transplantation."

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap